TL;DR
This study successfully developed and validated a radiolabeled version of the ASO tofersen ([<sup>99m</sup>Tc]Tc-MAG3-tofersen) for non-invasive imaging of drug distribution in the central nervous system (CNS). The findings demonstrate broad uptake in the brain and spinal cord across rodents, nonhuman primates, and humans, providing crucial insights into ASO pharmacokinetics and supporting the development of future CNS-targeted therapies.
What Problem Does This Paper Address?
Antisense oligonucleotides (ASOs) are a promising class of therapeutics, but their distribution and behavior within the central nervous system (CNS), particularly in humans, remain poorly understood. This lack of detailed pharmacokinetic and biodistribution data hinders the optimization of ASO delivery for neurological diseases. Specifically, characterizing how ASOs reach target brain regions and how they are cleared is essential for designing more effective treatments. This paper addresses this gap by developing a method to visualize and quantify ASO distribution in vivo, bridging the divide between preclinical models and human studies.
Methods
The core innovation of this study is the development of a radiolabeled tracer, [<sup>99m</sup>Tc]Tc-MAG3-tofersen. Tofersen, an ASO approved for SOD1-ALS, was chemically modified by conjugating it to a MAG3 moiety. This moiety acts as a chelator, allowing it to bind the radioactive isotope technetium-99m (<sup>99m</sup>Tc). This radiolabeled compound was designed to serve as a proxy for the unlabeled therapeutic drug.
The researchers then employed Single-Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) imaging to track the distribution of this radiolabeled tracer. Preclinical studies were conducted in rats and nonhuman primates (NHPs) where the tracer was administered intrathecally (directly into the cerebrospinal fluid via lumbar puncture), mimicking the clinical route of administration. In parallel, a first-in-human imaging trial was performed with healthy volunteers, also receiving intrathecal administration of the radiolabeled tracer alongside a therapeutic dose of unlabeled tofersen. This multi-species approach allowed for comparison of ASO biodistribution and pharmacokinetics across different biological systems.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- Bridging the Preclinical-Human Divide: The development of [<sup>99m</sup>Tc]Tc-MAG3-tofersen provides a crucial tool for directly comparing ASO behavior in animal models to humans, a significant step in translating preclinical findings.
- Consistent Broad CNS Uptake: Across all species studied (rats, NHPs, and humans), the radiolabeled ASO showed widespread distribution throughout the spinal cord and brain after intrathecal administration. This supports the hypothesis that ASOs can access these critical areas.
- Species-Specific Clearance Kinetics: While initial distribution patterns were similar, the clearance of the ASO from the CNS differed notably between humans and preclinical models. Humans showed increasing brain uptake in the initial hours, whereas rodents and NHPs exhibited declining concentrations. Similarly, spinal cord clearance plateaued earlier in animals compared to humans.
- Peripheral Clearance: In all species, the primary routes of peripheral clearance for the ASO were identified as the liver and kidneys, which is a common pathway for many drug molecules.
- Safety and Tolerability: The human trial demonstrated that co-administering the microdose of radiolabeled tofersen with a therapeutic dose of unlabeled tofersen was well-tolerated, with no serious adverse events reported. Human dosimetry estimates also fell within safe radiation dose limits.
Key Results
- Radiochemical Purity: The synthesized [<sup>99m</sup>Tc]Tc-MAG3-tofersen tracer was prepared with greater than 99% radiochemical purity.
- Proxy Validation: In rats, the biodistribution of [<sup>99m</sup>Tc]Tc-MAG3-tofersen was shown to be a reliable proxy for unlabeled tofersen.
- Human Brain Uptake: In healthy volunteers, human brain uptake of the radiolabeled ASO increased during the first 4 hours post-injection.
- Spinal Cord Clearance: Tracer clearance from the lumbar spine plateaued after 6 hours in rodents and NHPs but continued to decrease in humans over the 24-hour imaging period.
- Dosimetry: Human dosimetry estimates were within safe radiation dose levels, with an estimated effective dose of 0.62 ± 0.112 mSv.
Limitations and Future Work
The authors acknowledge several limitations. Firstly, SPECT imaging, while valuable, has relatively low spatial resolution compared to techniques like PET. This limits the ability to assess ASO distribution in very small brain regions or differentiate between spinal cord and CSF with high precision. Secondly, the relatively short half-life of <sup>99m</sup>Tc (approximately 6 hours) constrained the imaging analysis to a 24-hour window, which is significantly shorter than the weeks-to-months half-life of ASOs themselves.
Future work could involve using longer-lived radioisotopes (e.g., <sup>89</sup>Zr) or alternative imaging modalities like PET to achieve higher resolution and longer observation periods. This would allow for a more comprehensive understanding of ASO pharmacokinetics over their full duration of action. The study also suggests that while rodent and NHP models are suitable for initial testing, the observed kinetic differences in humans highlight the importance of direct human imaging studies for accurate pharmacokinetic profiling. The developed radiolabeling approach is also presented as a versatile platform that can be applied to other ASOs, enabling broader drug development efforts.
Summary updated